Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.09 (market cap $9.43B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.35. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| BIO | NVDL | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $43.02 |
52-Week Low | $241.71 | $21.76 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.00, up 4.77% in the last 24 hours. The technical outlook is bullish, supported by moving averages, though the RSI suggests mild overbought conditions. Recent corporate actions include two stock splits effective June 2026. The fund provides leveraged exposure to NVIDIA, which remains a dominant force in AI, but key financial ratios for NVDL itself are not publicly detailed as it is an ETF tracking daily returns.
The outlook for NVDL hinges on NVIDIA's performance, with bullish technicals and media sentiment pointing to potential gains, especially around earnings. However, risks include high volatility from daily leverage reset, which can amplify losses during NVIDIA downturns, as seen in past sharp declines. Investors should weigh the leveraged structure's compounding effects against NVIDIA's strong AI-driven growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
